Impact of Atorvastatin Versus Rosuvastatin on 25 Hydroxy Vitamin D Levels in Patients With Acute Coronary Syndrome
Recruiting
Phase 4
Interventional Study
Acute Coronary Syndromes
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 65
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Supportive Care
- Participants needed
- 152 (estimated)
- Sponsor
- King Edward Medical University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
there will be 2 groups of patients with acute coronary syndrome. The patients will receive one of the 2 study drugs and impact on raising Vitamin D level will be seen after 6 months
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
Acute Coronary Syndrome
25 OH-Vitamin D levels between 30-70ng/ml
Exclusion Criteria:
Hypercalcemia
hypocalcemia
pregnancy
lactation
hypersensitivity to statins
hypothyroidism
Deranged LFTs \& RFTs
Use of following within last 3 months (Vitamin D Supplements, lipid low…
Contacts